Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease |
| |
| Institution: | 1. Leidos Inc., Atlanta, GA, United States;2. Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States;3. Division of Viral Hepatitis, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States;1. State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150001, China;2. Institute of Animal Husbandry and Veterinary Sciences, Hubei Academy of Agricultural Sciences, Key Laboratory of Prevention and Control Agents for Animal Bacteriosis (Ministry of Agriculture), Hubei Key Laboratory of Animal Embryo and Molecular Breeding, Wuhan, Hubei 430064, China;3. State Key Laboratory of Agricultural Microbiology, The Cooperative Innovation Center for Sustainable Pig Production, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei 430070, China;4. College of Life Sciences, Central China Normal University, Wuhan, Hubei 430079, China;1. Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA;2. Center for Infectious Disease and Immunology, Rochester General Hospital Research Institute, Rochester, NY, USA;1. Department of Internal Medicine, Mito Kyodo General Hospital, University of Tsukuba, 3-2-7, Miyamachi, Mito, Ibaraki, 310-0015, Japan;2. Center for Global Health, Mito Kyodo General Hospital, University of Tsukuba, 3-2-7, Miyamachi, Mito, Ibaraki, 310-0015, Japan;3. Office of Medical Education, Center for Infectious Diseases, International, University of Health and Welfare, 4-3, Kozunomori, Narita, Chiba, 286-8686, Japan;1. Unit of Infectious Diseases, Department of Medicine, Karolinska Institutet, Stockholm, Sweden;2. Department of Infectious Diseases, Karolinska University Hospital Huddinge, Stockholm, Sweden;3. Division of Virology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;1. Department of Obstetrics and Gynecology, Medical University of South Carolina, 29425, USA;2. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston 29425, USA;3. Divison of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston 29425, USA;4. Chief of No. 5 Biologicals Department, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kuming 650118, China;5. The Sixth People''s Hospital of Xinjiang Uyghur Autonomous Region, Kashi East Road 100 North Lane Of Xinshi District, Xinjiang, Urumqi 830013, China;6. The 302 Hospital of PLA, Treatment and Research Center for Infectious Diseases, Beijing 100039, China |
| |
| Abstract: | BackgroundInfection with hepatitis A and hepatitis B virus can increase the risk of morbidity and mortality in persons with chronic liver disease (CLD). The Advisory Committee on Immunization Practices recommends hepatitis A (HepA) and hepatitis B (HepB) vaccination for persons with CLD.MethodsData from the 2014 and 2015 National Health Interview Surveys (NHIS), nationally representative, in-person interview surveys of the non-institutionalized US civilian population, were used to assess self-reported HepA (≥1 and ≥2 doses) and HepB vaccination (≥1 and ≥3 doses) coverage among adults who reported a chronic or long-term liver condition. Multivariable logistic regression was used to identify factors independently associated with HepA and HepB vaccination among adults with CLD.ResultsOverall, 19.4% and 11.5% of adults aged ≥ 18 years with CLD reported receiving ≥1 dose and ≥2 doses of HepA vaccine, respectively, compared with 14.7% and 9.1% of adults without CLD (p < .05 comparing those with and without CLD, ≥1dose). Age, education, geographic region, and international travel were associated with receipt of ≥2 doses HepA vaccine among adults with CLD. Overall, 35.7% and 29.1% of adults with CLD reported receiving ≥1 dose and ≥3 doses of HepB vaccine, respectively, compared with 30.2% and 24.7% of adults without CLD (p < .05 comparing those with and without CLD, ≥1 dose). Age, education, and receipt of influenza vaccination in the past 12 months were associated with receipt of ≥3 doses HepB vaccine among adults with CLD. Among adults with CLD and ≥10 provider visits, only 13.8% and 35.3% had received ≥2 doses HepA and ≥3 doses HepB vaccine, respectively.ConclusionsHepA and HepB vaccination among adults with CLD is suboptimal and missed opportunities to vaccinate occurred. Providers should adhere to recommendations to vaccinate persons with CLD to increase vaccination among this population. |
| |
| Keywords: | Hepatitis A vaccination Hepatitis B vaccination Chronic liver disease National Health Interview Survey |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
